As of December 2024, the company's Board formed a Special Committee to explore strategic opportunities to create and enhance value for investors. In June 2025, the company rebranded to TAO Synergies Inc. and shifted its strategic focus, with the common stock beginning to trade under the new ticker symbol TAOX on or about July 1, 2025. The company is exploring various alternatives to its previous research and development programs while expecting a dramatic decline in its cash burn rate.
Cyborg Score Rationale
The company's lead program (Bryostatin-1 for advanced Alzheimer's) failed its primary endpoint in its Phase 2 trial in December 2022. However, the company maintains a robust financial position with approximately $19.6 million in cash as of September 30, 2024. Recent strategic repositioning suggests management is actively seeking new therapeutic platforms.
Top Insights
Bryostatin-1 failed its primary endpoint in NIH-sponsored Phase 2 trial for advanced Alzheimer's disease (December 2022), with only 1.4 points vs. 0.6 points placebo improvement.
Company maintains a strong balance sheet with $19.6 million in cash and only 1.3 million common shares outstanding as of September 30, 2024.
Rebranded to TAO Synergies Inc. effective June 26, 2025, with ticker change to TAOX in July 2025, signaling a strategic pivot.
Management exploring promising drug development platforms and new technologies while expecting dramatic reduction in cash burn rate.
Named Competitors
Neurodegenerative Disease Therapeutics — Large pharma with neuroscience programs
Drug Development Platform — Clinical-stage biotech company
AI-Driven Drug Discovery — AI-enabled drug discovery platform
Recent Developments
(June 2025) Rebranded to TAO Synergies Inc.; common stock began trading under ticker TAOX
(December 2024) Board formed Special Committee to explore value creation opportunities
(September 2024) Raised $5.0 million financing with existing investors via Series C convertible preferred stock
Open the full interactive Synaptogenix, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.